Without prescription.

Instruction

for medical use:

MAALOX®

INN: aluminium hydroxide and magnesium hydroxide;

physicochemical characteristics: mint flavored, white colored, colloidal suspension; composition: each 100 ml contains: aluminium hydroxide - 3.5 g, magnesium hydroxide - 4.0 g; excipients: methylparahydroxybenzoate - 0.1 g, propylparahydroxybenzoate - 0.05 g, citric acid, essential oil of peppermint, mannitol, sorbitol, concentrated HCI, sodium saccharine, purified water.

Pharmaceutical form. Oral suspension.

Pharmacotherapeutic category. Locally acting antacid. ATC - A02A D01.

Pharmacological properties. MAALOX® is well-balanced combination of aluminium hydroxide and magnesium hydroxide with high acid-neutralization capacity and protective effect of the oesophago-gastro-duodenal mucosa. Acid-neutralizing capacity of 1 g suspension is > 24.5 ml of 0.1 N HCI. Use as antacid and adsorbent.

Pharmacokinetic properties. The drug is not absorbed from gastro-intestinal tract into systemic circulation and does not produce any systemic effects.

Indications. Functional dyspepsia and stomach discomfort as a result of dietary disorders, medicines usage, abuse of alcohol, coffee, smoking; gastroesophageal reflux disease. Adjuvant therapy of the acute and chronic gastritis, gastric and duodenal ulcer disease.

Dosage and administration. 15 ml (1 table spoon or 1 sachet) 1-1.5 hour after meal or in case of painful attacks. Mix the content before opening.

Undesirable effects. Related to aluminium hydroxide: phosphorus depletion in case of prolonged use or high doses.

Contraindications. Severe kidney failure.

Interactions with other medical products. When MAALOX® is taken simultaneously with one of the following drugs- indomethacin, salicylates, antihistamins H2-blockers, beta-blockers, aminazynum, diflunisal, isoniazide, phenytoin, tetracyclines, phosphorus containing medicines: the absorption of listed drugs is reduced.

Overdosage. By current time there are no reports about the complications caused by overdosage of MAALOX®.

Special precautions for use: MAALOX® should be taken 2 hours before or 2 hours after drugs listed in "Interactions with other medical products" section.

Storage. Store in dry place at room temperature. Keep out of the reach of children.

Shelf life 3 years.

Without prescription.

Nature and contents of container. 30 sachets of 15 ml in carton box. -.

Licence holder. "Theraplix" of Aventis Pharma, France.

Manufacturer. "Aventis Pharma Specialites", France; "Farmatis", France. Address. 17 Ruee la Vanne, 92547 Montrouge Cedex, France.

Task 1. Translate the names of the parts of the drugs’ annotations.

physicochemical characteristics
contains
Pharmaceutical form.
Pharmacotherapeutic category
Pharmacological properties
Indications
Dosage and administration.
Undesirable effects.
Contraindications.
Interactions with other medical products
Overdosage.
Special precautions for use
Shelf life
Without prescription
Manufacturer.

CHEMICAL GROUP
PHARMACOLOGICAL PROPERTIES
WAY OF USE/ POSOLOGY
INDICATIONS
CONTRA-INDICATION
PRESENTATION/ PRESENTATION FORM
INTERACTION WITH OTHER DRUGS
Incompatibilities
Adverse reactions/ Side Effects
CONDITIONS OF STORAGE
Supplied
Manufacturer
Exp. term /shelf lihe

Task 2. Translate the names of the parts of the drugs’ annotations/ other variants

Task 3. Name the part of the annotation

It is administered as a single therapeutic agent or as an adjuvant in the therapy of acute and chronic hepatitis, cirrhosis of the liver and fatty degeneration of liver (steatosis), some inborn diseases in bilirubin metabolism (Crigler-Najjar syndrome, Rotor-Stranski, Dubin Johnson). It is prophylactically used in drug, toxic and radiation impairment of the liver.

………………………..

In a dry, humidity-protected place at temperature of 15° - 25° C……………………………..

The drug is administered in a dose of 2 tablets, 3 times daily, except otherwise recommended by your physician. The daily dose can be increased in accordance to physician's opinion. It is usually administered prophylactically in a dose of 1 tablet. 3 times daily. The therapeutic course should not be shorter than 3 months The daily dose and duration of treatment of children is prescribed by the physician.

The tablets are taken with a little liquid during meals, not chewed…………………………

Packages of 80 coated tablets of 35 mg. Packages of 500 coated tablets of 35 mg…………………….

Protect from light. Store below 30° C………………………..

The tolerance of the drug is very good when administered in therapeutic doses. Stomach discomfort and mild diarrhea can be observed very rarely……………………

Each ml contains 1 mg of dexamethasone (INN). Excipients: s. q. (benzalkonium chloride as preservative)…………..

MAXIDEX is indicated for conditions that generally respond to corticosteroids, such as:

Inflammatory conditions of the anterior pole of the eye: chronic or acute anterior uveitis, iritis, iridocyclitis, cyclitis and herpes zoster (not to be used for herpes simplex).

External diseases: non-specific superficial keratitis, phlyctenular kerato-conjunctivitis, conjunctivitis (vernal, allergic, catarrhal).

It is very effective when allergy is the essential factor. Recurrent marginal ulcer.

Corneal injury caused by a foreign body. Chemical or thermal burns.

In post surgery, to reduce the inflammatory reaction.

Anterior uveitis associated with secondary glaucoma, once glaucoma has been controlled (to treat uveitis)………………………………

To obtain the desired therapeutic effect, this drug should be administered strictly according to the prescription of your physician - in the prescribed dose and duration of the therapeutic course.

If during the treatment some of the indicated unfavourable drug reactions or any other manifestations occur, contact immediately your physician.

Pregnancy and breast feeding: The drug can be used during pregnancy and breast feeding period only in compliance with physiciarf s prescription and supervision.

Usage by drivers and machine operators: Carsil can be administered during driving and machine operation…………..

Дата добавления: 2015-10-26